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Based on the analysis conducted by the World Health 
Organization regarding the life expectancy in 35 Or-
ganisation for Economic Co-operation and Develop-
ment (OECD) countries, South Korea’s life expectancy 
is predicted to rank first in the world by 2030, with 
the life expectancy for women reaching 90.82 years. 
In other words, the importance of women’s health and 
the quality of life (QoL) after menopause is increasing. 
The most effective treatment for vasomotor symptoms 
(VMS) and genitourinary syndrome of menopause 
(GSM) is menopausal hormone therapy (MHT), which 
is also effective in preventing osteoporosis. MHT is an 
effective therapy that offers more advantages than dis-
advantages for women aged less than 60 years or who 
have had menopause for less than 10 years. Therefore, 
the purpose of these guidelines is to provide help by 
sharing accurate knowledge and treatment methods 
regarding MHT based on recent research findings.
1. Examinations required prior to receiving 
MHT
Points to consider prior to initiating MHT include 
checking the indications and contraindications of 
MHT, which requires history recording, physical ex-
aminations, and other tests. Because the symptoms of 
menopause are varied, customized tests should be con-
ducted for each risk factor based on the basic examina-
tion conducted according to the life cycle necessary for 
women [1-3].
The basic examination, which is a general exami-
nation conducted according to the life cycle, should 
identify lifestyles such as smoking and drinking habits; 
mental diseases such as depression; and with family his-
tory for diseases such as Alzheimer’s disease, osteopo-
rosis, diabetes, endometrial cancer, breast cancer, liver 
disease, thyroid disease, cardiovascular disease, and ve-
nous thromboembolism via history taking. In addition, 
the basic examination should include a physical exami-
nation for height, weight, and blood pressure as well as 
the pelvis, breast, and thyroid. Blood tests include tests 
for liver function, kidney function, anemia, and fasting 
blood sugar as well as lipid examination, followed by 
mammography, bone mineral density (BMD) test, and 
Pap smear screening [3]. Furthermore, it is reasonable 
to regard pelvic ultrasonography as part of the basic 
examination in Korea considering its cost-effectiveness. 
Elective examinations such as thyroid function test, 
breast ultrasonography, and endometrial biopsy are 
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customized to fit individuals’ risk factors. Depending 
on clinical manifestations and individual risk factors, 
the basic examinations and elective examinations are 
conducted at an interval of 1–2 years. MHT is used 
to prevent and treat symptoms and physical changes 
caused by estrogen deficiency, vasomotor symptoms, 
atrophy symptoms of the urogenital system, postmeno-
pausal osteopenia, and osteoporosis. In the case of pre-
mature ovarian insufficiency (POI), MHT can be used 
at least until the mean age of menopause regardless of 
symptoms [1,2]. In case of undiagnosed vaginal bleed-
ing, estrogen-dependent malignant tumors (such as 
endometrial cancer), breast cancer, active thromboem-
bolism, active liver diseases, and gall bladder diseases, 
MHT should not be used [1,2]. Because the symptoms 
of menopause vary widely depending on an individual’s 
physical, mental, social, cultural, and racial features, the 
physician is recommended to conduct an individual-
ized menopause consultation and examination prior to 
MHT based on general principles of clinical examina-
tion as well as considering individual differences [3].
Key points:  Examinations required prior to 
receiving MHT
1.  The examinations required to be conducted pri-
or to MHT are history taking, physical examina-
tion, and examinations for liver function, kidney 
function, anemia, fasting blood sugar, and blood 
tests of serum lipid profile, followed by mam-
mography, BMD test, and Pap smear screening.
2.  The elective examinations required to be con-
ducted prior to MHT are thyroid function test, 
breast ultrasonography, and endometrial biopsy 
conducted as individualized tests according to 
individual risk factors. Depending on clinical 
manifestation and individual risk factors, the 
basic examinations and elective examinations are 
conducted at an interval of 1–2 years.
2. MHT for women in menopausal transition
Menopausal transition refers to the period from the 
moment of increased variation in menstrual cycle until 
the moment immediately prior to the last day of men-
struation. It varies among individuals and is a period 
that often includes vasomotor symptoms such as hot 
flushes alongside frequent or excessive menstruation. 
Hot flushes vary among individuals but may appear 
from 1 year to 3 years prior to the last day of menstrua-
tion and are especially severe around the last day of 
menstruation. They may even last for several years. 
Approximately 75% of women aged between 45 years 
and 55 years suffer from symptoms of menopause, 
which may lead to low self-esteem, sleep disorder, and 
feelings of decreased energy. To evaluate the ovarian 
reserve during menopausal transition, measuring the 
serum level of anti-mullerian hormone (AMH), day 3 
follicle-stimulating hormone (FSH), estradiol (E2), and 
ovarian antral follicle count (AFC) using pelvic ultraso-
nography is possible, but they are not used as indicators 
for predicting menopause. Additionally, because the 
function of the ovaries changes during this period, it is 
advised not to conduct a hormone test for menopause 
diagnosis [4].
Undergoing treatment for menopausal transition 
should be primarily decided according to the frequency 
and severity of the symptoms of menopause. Even in 
the case of menstruation, if a severe hot flush is expe-
rienced, a consultation is advised in order to discuss 
the necessary treatment to improve symptoms [4]. 
It is also possible to try alleviating the symptoms via 
improvement of lifestyles such as weight loss, stress 
reduction, hypnosis, and cognitive behavioral therapy. 
Medications such as omega-3, vitamin E, Cimicifuga 
racemosa, isoflavone, and soybean may be effective, but 
they are not more effective than placebo. In contrast, 
S-equol, a metabolite of soy isoflavone, seems to show 
slightly higher effectiveness than placebo [4].
Hormone therapies for treating the symptoms of 
menopause during menopausal transition are combi-
nation therapy of levonorgestrel releasing-intrauterine 
system (LNG-IUS) with oral or percutaneous estrogen, 
low-dose combined oral contraceptives (COCs), and 
estrogen–progestogen therapy (EPT) [4].
EPT is effective not only for treating women after 
menopause but also for controlling the symptoms of 
menopause in women in menopausal transition. How-
ever, the dose used in general MHT is very low com-
pared with that used for treating women before meno-
pause, and consequently, breakthrough bleedings could 
frequently occur. If contraception is simultaneously 
needed, the use of low-dose COCs is recommended. 
Low-dose COCs are effective for controlling irregular 
bleeding and alleviation of symptoms of hot flush [4].
In the case of using low-dose COCs, because the 
symptoms of menopause could worsen during the 
7-day pill-free period, the use of continuous COCs or 
COCs such as Qlaira® with a shorter pill-free period 
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is recommended. With regard to the safety of low-
dose COCs, if there are no risk factors involved such as 
obesity, smoking, high blood pressure, and other car-
diovascular diseases, it may be used carefully from 40 
to 55 years of age. However, careful screening of each 
individual’s risk factors is important [5-7].
The use of oral or percutaneous estrogen therapy (ET) 
together with LNG-IUS is not only effective for allevi-
ating the symptoms of menopause but also for prevent-
ing endometrial hyperplasia. Even in the case of a nor-
mal menstrual cycle, if the symptoms of menopause are 
severe, the use of a combination therapy of low-dose 
percutaneous estrogen and LNG-IUS could effectively 
control a hot flush [8]. In addition, some reports have 
shown that it could help improve symptoms that ap-
pear during menopausal transition such as depression, 
reduced quality of sleep, and increased anxiety [9,10].
However, as mentioned earlier, it remains unclear how 
ET initiated at this stage would affect cardiovascular 
diseases and breast cancer in the long term. Therefore, 
treatment during the menopausal transition period 
should be primarily based on the frequency and sever-
ity of the symptoms, and different treatment methods 
should be applied to improve symptoms according to 
the individual’s risk factors [11].
Key points:  MHT for women in menopausal 
transition
1.  It is advised not to conduct a hormone test to 
diagnose menopause during menopausal transi-
tion.
2.  Hormone therapy during menopausal transition 
should primarily be conducted based on the fre-
quency and severity of symptoms, and lifestyle 
adjustments and use of adjuvant therapy could 
be partially effective.
3.  EPT, low-dose COCs, and combination therapy 
of LNG-IUS with oral or percutaneous estrogen 
could be employed as individualized treatments 
depending on individual risk factors for the pur-
pose of improving symptoms.
3. Vasomotor symptoms and quality of life
3-1. Vasomotor symptoms
Hot flush, a common VMS, suddenly appears in the 
face and the upper body and spreads to the rest of the 
body. It usually lasts for approximately 2–4 minutes. 
Anxiety, shivering, palpitation, or perspiration may oc-
cur alongside, and night sweat is linked to sleep disor-
der.
The prevalence rate of VMS differs according to 
region and race. A lower prevalence rate of VMS is 
observed among Asians than among Westerners. The 
prevalence rate in Europe is 74%, North America 36%–
50%, Central and South America 45%–69%, and Asia 
22%–63% [12]. VMS are known to be highly related to 
the reduction of physical activity, low socioeconomic 
status, symptoms of anxiety and depression, hysterec-
tomy, and smoking and the symptoms increase as body 
fat increases [13,14].
Most severe VMS appear within 1–2 years from the 
last day of menstruation and usually continue for about 
4–5 years. However, there are cases in which the symp-
toms last for more than 12 years, which is reported to 
be 10% of the total cases; therefore, the symptom dura-
tion greatly varies [13,15].
Similar to standard-dose MHT, low-dose MHT is re-
ported to be effective for treating VMS [16].
In a research with a multistage stratified random 
sampling design conducted in 2010 that targeted 40– 
60-year-old South Korean women in menopause or 
menopausal transition, 41.6% of women in menopausal 
transition, 53.1% of women in early-phase menopause, 
and 36.5% of women in late-phase menopause were 
shown to have experienced VMS [17]. In case of expe-
riencing VMS, many women aged less than 45 years 
(50%) were shown to experience only hot flush as a 
monosymptom, whereas for women aged 45–60 years, 
the cases in which both hot flush and sweating were 
experienced increased up to 70% [17]. The results of a 
survey conducted by Korean Gallup Epidemiology Re-
search in 2001 that targeted women aged 50–59 years 
in menopause showed that the main reason for receiv-
ing MHT was experiencing menopause symptoms, and 
62.7% women reported that it was helpful [18].
In terms of the degree of improvement of VMS ac-
cording to dose, a placebo showed 20%–40% reduc-
tion of symptoms, and the effect of extreme low-dose 
therapy, low-dose therapy, and standard-dose therapy 
in alleviating symptoms was 55%, 60%–70%, and 80%–
90%, respectively, in MHT [19-21].
In terms of the degree of improvement of VMS for 
non-hormonal therapies, selective serotonin recep-
tor inhibitor (SSRI)/selective norepinephrine receptor 
inhibitor (SNRI) showed 40%–65%, gabapentin (900 
mg/day) showed 50%, and pregabalin (150 mg/day) 
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showed 65% improvement of symptoms [22,23].
Progestogen (medroxyprogesterone acetate [MPA] 
10 mg/day, oral megestrol acetate 20 mg/day, and MP 
300 mg/day) is known to alleviate VMS with a minimal 
risk, and it is highly effective in the case of severe VMS. 
The symptoms are less likely to recur when progesto-
gen therapy is discontinued compared with the discon-
tinuation of estrogen therapy [23,24].
In the case of MHT discontinuation, a report showed 
that VMS recurred at 50% and at most 87%; nonethe-
less, the severity of VMS in the case of recurrence was 
not as bad as that before starting MHT [25]. There is no 
difference in the recurrence rate of symptoms whether 
MHT is suddenly or gradually discontinued by eventu-
ally reducing the dose [2].
3-2. Quality of life 
Evaluation of the QoL may be divided into the follow-
ing criteria: health-related QoL (HRQoL), menopause-
specific QoL (MSQoL), and global QoL (GQoL).
MHT reportedly not only enhances MSQoL by 
improving menopause symptoms but also increases 
GQoL. In particular, MHT improves HRQoL and 
MSQoL of women experiencing severe menopause 
symptoms.
The Korean epidemiology research on the QoL and 
menopause symptoms of women in menopause also 
showed a similar correlation between the two, but 
women receiving MHT were shown to have a high QoL 
in aspects such as VMS, psychosociological changes, 
and physical changes [26]. In an evaluation of QoL us-
ing the SF-36 questionnaire, the group receiving MHT 
was shown to have a higher QoL score than the group 
not receiving MHT [27]. In another study, there was an 
increase in the score of Women’s Health Questionnaire 
(WHQ) and an improvement of physical symptoms, 
depression symptoms, and sleep disorder in the treat-
ment group receiving MHT [28].
Based on the analysis of WHQ scores, low-dose MHT 
(E2 1 mg/norethindrone acetate [NETA] 0.5 mg) and 
tibolone have been reported to improve QoL. Tibolone 
mostly improved sexual function while showing effec-
tiveness in improving VMS. MHT enhances the quality 
of sleep and reduces VMS and thus helps improve sleep 
disorder. In a study using a low-dose oral or percuta-
neous MHT (0.5 mg 17β-estradiol and 0.1–0.25 mg 
NETA) for 24 weeks, sleep disorder was improved by 
40%–50% [24]. When oral progestogen is used, there 
may be reduced waking up and increased sedation [2]. 
In addition, when a premenopausal woman reaches 
menopause while using SSRI to treat depression, com-
pared with SSRI therapy alone, SSRI in combination 
with estrogen is more effective in improving depression 
and shows a faster rate of treatment [29].
In contrast to the prevalent views, MHT is not as-
sociated with an increase in weight, and in fact, it 
helps treat the accumulation of abdominal fat during 
menopausal transition. In animal experiments, lack of 
estrogen led to accumulation of central abdominal fat, 
which was improved via injection of estrogen [22]. In 
many randomized controlled studies, MHT has been 
shown to reduce abdominal obesity [22]. In a research 
by the Women’s Health Initiative (WHI) on EPT, main-
taining MHT for 3 years was shown to help maintain 
underweight status and prevent transformation into 
android fat distribution [22]. ET improves the accumu-
lation of abdominal fat because it improves insulin sen-
sitivity and reduces the occurrence of type 2 diabetes, 
thereby reducing overall body fat [22].
Key points:  Vasomotor symptoms and quality 
of life
1.  Because VMS appear in relation to the reduction 
of estrogen levels in the central nervous system, 
MHT is the most effective treatment.
2. VMS are the main indications of MHT.
3.  Apart from VMS, MHT can treat other meno-
pause symptoms such as sleep disorder, depres-
sion, and musculoskeletal pain and enhance the 
overall QoL of women in menopause.
4.  MHT is not associated with increased weight; 
conversely, it helps improve the accumulation of 
abdominal fat.
5.  There is a tendency for symptoms to recur when 
therapy is discontinued.
4. Urogenital atrophy and sexual dysfunction
4-1. Urogenital atrophy
Urogenital atrophy has been newly renamed as GSM. 
The term includes all the symptoms and signs caused 
by changes in the bladder, urethra, vagina, and genitalia 
due to the decreased estrogen level during menopause 
and vaginal atrophy. The main symptoms are vaginal 
dryness, burning sensation, and discomfort; sexual 
symptoms such as pain due to decreased lubrication; 
and urinary symptoms such as painful urination, re-
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current urinary tract infections (UTIs), and urinary 
urgency [30].
GSM chronically progresses and requires long-term 
treatment because the symptoms recur if treatment is 
stopped. The principle of this treatment is to alleviate 
the symptoms by normalizing the physiological envi-
ronment of the urogenital organs. For the treatment of 
moderate or severe vaginal atrophy, both systemic and 
topical estrogens are effective. They help recover nor-
mal vaginal flora, increase the quantity of vaginal dis-
charge by improving the division of the vaginal epithe-
lium, induce proliferation of capillaries, and improve 
the maturation index of the vaginal epithelium [31-33]. 
In particular, low-dose vaginal estrogen is effective and 
safe, although the quantity of absorption in the whole 
body is minimal. All types of topical estrogen medicine 
(cream, vaginal tablet, and vaginal ring) are effective in 
reducing the symptoms and signs of vaginal atrophy. 
However, because there is a potential risk of increasing 
the estrogen level in the blood even by the slightest de-
gree, in women with breast cancer, especially those us-
ing an aromatase inhibitor to reduce the estrogen level, 
a breast cancer specialist must be consulted regarding 
the vaginal application of low-dose estrogen [34]. Be-
cause there is no clinical data to guarantee the safety of 
the endometrium for a long-term application of more 
than 1 year, the duration of using low-dose vaginal es-
trogen should be limited to less than 1 year, and after-
ward, it must be used along with the evaluation of the 
endometrium.
Ospemifene and dehydroepiandrosterone (DHEA) 
vaginal agents are non-estrogen medications that im-
prove the symptoms of vaginal atrophy and dyspareu-
nia. Ospemifene, which is a selective estrogen receptor 
modulator (SERM), is more effective than a lubricant 
in reducing dyspareunia by treating moderate or severe 
vaginal atrophy in menopausal women. Hence, it can 
be considered for women who are not suited to receive 
vaginal estrogen treatment [35].
Vaginal DHEA has received FDA approval as a medi-
cine for the treatment of GSM because it reduces vagi-
nal dryness and dyspareunia as well as vaginal acidity 
by recovering the thickness and safety of epithelial cells 
and increasing the quantity of vaginal discharge [36].
The North American Menopause Society (NAMS) 
recommends the use of a moisturizing cream or lubri-
cant as the primary treatment for vaginal atrophy. If a 
lubricant and moisturizer are frequently used, they im-
prove the symptoms of vaginal dryness, reduce discom-
fort, and maintain vaginal discharge during sex but do 
not transform the contracted internal environment of 
the vagina. The use of a vaginal moisturizer, lubricant, 
and regular sexual intercourse help in the treatment of 
vaginal atrophy. Some studies show that a vaginal mois-
turizer has a similar effect to topical estrogen; thus, it 
could be recommended to women who avoid using 
MHT [34].
Recently, carbon dioxide laser therapy has been shown 
to improve sexual function and alleviate symptoms 
such as dyspareunia, itchiness, burning sensation, and 
dryness by improving the quantity of glycogen inside 
the vaginal epithelial cells and encouraging remodel-
ing of vaginal connective tissues for women suffering 
from vaginal atrophy. It is predicted to become a suit-
able treatment for patients who simultaneously suffer 
from symptoms of GSM, which leads to a huge concern 
about MHT [37]. However, because there have been 
reports of chronic pain, burning sensation, and dyspa-
reunia after receiving laser therapy and the U.S. FDA 
warned against the safety and effectiveness of laser 
therapy in July 2018, attention should be paid toward 
future research findings [38,39].
Pelvic floor muscle training, vaginal ring insertion, 
and topical estrogen treatment improve the function 
of vaginal epithelial cells and accelerate the ingrowing 
of connective tissue. Vaginal estrogen reduces urinary 
urgency, urinary frequency, overactive bladder, and uri-
nary incontinence by reducing the contraction of blad-
der muscles via increasing the blood flow around the 
bladder neck and urethra. In contrast, systemic ET in-
creases the occurrence of urgency urinary incontinence 
and stress urinary incontinence [40-43]. In the case 
of women with existing symptoms of urinary inconti-
nence, the therapy worsens the symptoms, which may 
lead to a reduced QoL [40-43]. To treat the symptoms 
of an overactive bladder, changes in lifestyles and blad-
der training are very important and are recommended 
as the primary treatment methods. The systemic ET 
shows a similar effect to a placebo with regard to the 
treatment of the symptoms of nocturia and urinary 
frequency, but it is more effective than a placebo for 
the treatment of symptoms. Combined administration 
of vaginal estrogen and antimuscarinic drug is more 
suitable, and topical estrogen is considered to play an 
important role in treating an overactive bladder. Hence, 
the combination therapy of an antimuscarinic drug and 
topical estrogen is the primary drug therapy for meno-
pausal women with symptoms of an overactive bladder 
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[44-46]. Topical ET was shown to be effective in pre-
venting recurrent UTIs by recovering microbiological 
changes that occurred within the vagina after begin-
ning menopause and by reducing vaginal acidity, but 
systemic ET was not effective for preventing recurrent 
UTIs [47].
Key points: Urogenital atrophy
1.  Urogenital atrophy has been newly renamed as 
GSM, which includes all the symptoms caused 
by changes in the contraction of the bladder, ure-
thra, vagina, and genitalia due to the decreased 
estrogen level during menopause and vaginal 
atrophy.
2.  The use of topical estrogen is recommended for 
the treatment of GSM and recurrent UTIs.
3.  Lubricants, vaginal moisturizers, ospemifene, 
and vaginal DHEA are non-estrogen therapies 
available for treating urogenital atrophy, but la-
ser therapy could be considered an additional 
therapy.
4.  For menopausal women with symptoms of an 
overactive bladder, the primary drug therapy is 
the combination therapy of an antimuscarinic 
drug and topical estrogen.
5.  Systemic ET is effective for treating vaginal atro-
phy but not effective for treating recurrent UTIs, 
overactive bladder, and urinary incontinence.
4-2. Sexual dysfunction
Increased age and decreased estrogen level lead to 
harmful effects on sexual function and reduce sexual 
desire and sexual response as well as cause vaginal dry-
ness and dyspareunia. They also cause sexual dysfunc-
tion even more in the case of surgical menopause, and 
it is highly possible that hypoactive sexual desire disor-
der (HSDD) develops as a result of various endocrine 
changes [48-52].
Measuring the level of sexual hormones is not help-
ful. The serum androgen test has been used to diagnose 
androgen deficiency in healthy women, but it is also 
not recommended because there is mostly inconsistent 
correlation between the androgen level and particular 
symptoms and signs. Especially in the case of sexual 
dysfunction, the role of vaginal atrophy must always 
be considered because the most common symptoms 
of vaginal atrophy are vaginal dryness and dyspareu-
nia, which significantly affect other aspects of sexual 
response (sexual desire, arousal, orgasm, and satisfac-
tion) [53]. Because female sex possesses a variety of 
fundamental characteristics, the effect of MHT on 
women’s sexual dysfunction cannot be clearly proven, 
and ET or EPT leads to improvement of sexual func-
tion and is especially effective in reducing dyspareunia 
in women in early menopause or with symptoms of 
menopause [31,54-57]. Tibolone is highly valuable for 
the treatment of women’s sexual dysfunction because 
it is known to show a significant effect on improving 
vaginal dryness, sexual desire, sexual arousal, and fre-
quency of sexual intercourse when compared with us-
ing estrogen or progestogen [58].
Systemic MHT and low-dose vaginal ET are effec-
tive in treating urogenital atrophy and improve sexual 
function by increasing vaginal lubrication, blood flow, 
and sensory function. Although ET is effective for the 
treatment of menopausal symptoms, it does not in-
crease sexual desire, arousal, and orgasm. In the case of 
women who are in need of systemic MHT expressing 
decreased sexual desire, percutaneous therapy is pre-
ferred to oral therapy because oral intake of estrogen 
reduces free testosterone by increasing sex hormone-
binding globulin (SHBG). An injection of testosterone 
for women suffering from sexual dysfunction due to 
decreased sexual desire improves sexual satisfaction, 
desire, arousal, and orgasm; thus, it is effective for both 
natural menopausal or surgical menopausal women 
and is effective regardless of whether the woman is 
receiving MHT. Testosterone is also effective for the 
treatment of sexual desire disorder and sexual arousal 
disorder, which are related to antidepressants [59-61]. 
Because the side effects of virilization due to testoster-
one therapy occur in proportion to the quantity admin-
istered, they may be reduced using the lowest quantity 
and medications suited for individual women [62,63]. 
Vaginal testosterone therapy, which is another treat-
ment option for GSM, improves dyspareunia, sexual 
desire, lubrication, and satisfaction when administrated 
alone or simultaneously with vaginal estrogen three 
times a week compared with a placebo [64-66].
Combination therapy of conjugated equine estrogen 
(CEE)–bazedoxifene also improves certain sexual func-
tions as well as genitourinary atrophy and dyspareunia 
in menopausal women [22,30,67].
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Key points: Sexual dysfunction 
1.  Increase in age and decreased serum estrogen 
levels lead to harmful effects on sexual function 
and cause dyspareunia and reduction of sexual 
desire and sexual response.
2.  Measuring the serum level of a sex hormone 
does not provide much help in diagnosing and 
treating sexual dysfunction, and conducting a 
blood test for testosterone to diagnose androgen 
deficiency in healthy women is not advised.
3.  When considering sexual dysfunction, the role 
of vaginal atrophy should always be considered.
4.  Systemic MHT and low-dose vaginal ET are 
effective for treating urogenital atrophy and 
improve sexual function by increasing vaginal 
lubrication, blood flow, and sensory function as 
well as improve dyspareunia in particular.
5.  Regarding female MHT for women with HSDD, 
percutaneous therapy is preferred over oral ther-
apy and tibolone is effective for treating female 
sexual dysfunction by increasing women’s sexual 
desire and arousal.
5. Coronary artery disease
Based on a meta-analysis of existing observational 
studies, hormone therapy reduces the risk of coronary 
artery disease by 28% and the mortality risk by 38% for 
current users [68]. In the Heart and Estrogen–Proges-
tin Replacement study (HERS) regarding the effect of 
hormone therapy on secondary prevention of coronary 
artery disease, CEE/MPA combination therapy showed 
no prevention effect and the risk increased by 50% 
in the first year of treatment but decreased thereafter 
[69,70]. Additionally, in a study by WHI about the ef-
fect on primary prevention of coronary artery disease, 
CEE/MPA combination therapy showed no primary 
prevention effect and the risk significantly increased by 
80% in the first year of treatment but showed trends of 
decline thereafter [71]. Conversely, in another study by 
WHI, CEE alone showed no prevention effect, but no 
increase in the early-phase risk was observed [72].
Considering that hormonal therapy did not prevent 
coronary artery disease in large-scale randomized con-
trol studies, unlike in observational studies, it is impor-
tant to note that the mean age of participants was older 
than 60 years old. It has been suggested that the results 
may not apply to women younger than 60 years who 
have recently experienced menopause.
Hence, their different characteristics compared with 
those of healthy, early menopausal women in observa-
tional studies are considered to be important aspects. 
Thus, women who are relatively older or for whom a 
long time has passed since menopause (average age, 
63.2 years) in the WHI study may not have experienced 
any significant effect on cardiovascular protection 
from hormone therapy as women in early menopause 
who are in good cardiovascular health. In a subsequent 
WHI analysis, the risk of coronary artery disease actu-
ally showed differences according to the starting period 
of hormone therapy since menopause. For women who 
started the therapy within 10 years of reaching meno-
pause, there was a trend toward reduced risk, whereas 
for women who started the therapy more than 20 years 
after reaching menopause, the risk significantly in-
creased [73].
Based on the result of analyzing 23 other clinical tests, 
the risk of coronary artery disease reduced by 32% for 
early menopausal women who have been in menopause 
for less than 10 years or women who were younger than 
60 years of age; however, for women aged 60 or more, 
such cardioprotective effect did not appear [74]. Based 
on the recent results of meta-analyzing 19 randomized 
controlled studies, starting hormone therapy within 
the first 10 years of menopause led to reduction of to-
tal mortality risk by 30% and cardiovascular mortality 
risk by 48% [75]. Additionally, women in their 50s who 
were previously enrolled in the ET arm of the WHI 
study showed significantly lower coronary artery calci-
fication scores than those who received placebo [76].
In the Danish Osteoporosis Prevention Study, when 
hormone therapy was conducted for 10 years with 1,000 
young menopausal women with the average age of 50 
years, there was a 52% reduction of the indicator, which 
is a combination of mortality, heart failure, or myocar-
dial infarction [77]. On the other hand, in the Kronos 
Early Estrogen Prevention Study (KEEPS), when hor-
mone therapy was administered for approximately 4 
years to young women with an average age of 52 years 
and all within 3 years of their final menstrual period, 
there was no significant difference in the rate of pro-
gression of carotid–intima-media thickness between 
the treatment and placebo groups. However, there was 
a nonsignificant trend for less accumulation of coro-
nary calcium in the hormone therapy arms than in the 
placebo arms [76]. In the Early versus Late Intervention 
Trial with Estradiol study, the use of hormone therapy 
for about 5 years for younger postmenopausal women 
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who were less than 6 years past menopause showed that 
the carotid–intima media thickness significantly de-
creased compared with the use of a placebo but showed 
no difference compared with the use of a placebo for 
women who were 10 or more years past menopause 
at the time of randomization [78]. In summary, such 
research findings strongly imply (“timing hypothesis” 
or “window of opportunity”) that the effect of hormone 
therapy on the cardiovascular system could differ de-
pending on the timing of initiation.
On the other hand, considering there were differences 
in the effect of hormone therapy on coronary artery 
disease between CEE alone and CEE/MPA combina-
tion therapy, attention must be paid to the type of hor-
mone used, particularly progestogen.
In contrast, the International Menopause Society 
(IMS) (2016) claimed that hormone therapy has shown 
to reduce the incidence of new-onset diabetes mellitus 
and has a beneficial effect on vascular function, lipid 
levels and glucose metabolism, which are risk factors 
for cardiovascular disorders [22]. There is strong evi-
dence showing that the mortality rate and the incidence 
of coronary artery disease are reduced if started around 
the time of menopause or under the age of 60 or within 
10 years of menopause. Progestin combination therapy 
also shows a similar tendency. Accordingly, hormone 
therapy does not increase the risk of coronary artery 
disease in young and healthy menopausal women, but 
it is not effective in case they already have the disease.
The mortality rate by ischemic heart diseases (myo-
cardial infarction and angina) in South Korean women 
was 25.0 deaths per 100,000 individuals in 2017, but for 
women aged above 65 years, the mortality rate was very 
high, reaching 148.8 deaths per 100,000 individuals. A 
more significant factor is that the mortality rate by isch-
emic heart diseases in OECD countries was reduced 
by 52% in 2016 compared with that in 1990; it was in-
creased in South Korea by 43%. Not only the mortality 
rate but also the economic burden of diseases are in-
creasing as the number of patients who received treat-
ments for ischemic heart diseases has almost doubled 
from 510,000 in 2004 to 860,000 in 2016, which led to 
the more than quadruple increase in health insurance 
fees from 2,900 billion won to 1 trillion 2,400 billion 
won; therefore, attention is required.
Key points: Coronary artery disease
1.  In women aged less than 60 years and/or within 
10 years of menopause with no evidence of car-
diovascular disease, the initiation of hormone 
therapy could be expected to reduce the inci-
dence of coronary heart disease and all-cause 
mortality.
2.  The effect of hormone therapy on coronary heart 
disease may differ depending on the use of pro-
gestogen and the timing of initiation.
3.  Currently, it is not recommended to initiate 
MHT solely for primary or secondary prevention 
of coronary heart disease.
6. Cerebral stroke
A meta-analysis including the WHI study found no 
increased risk of stroke in women aged less than 60 
years or who were fewer than 10 years from menopaus-
al onset [73,75,79,80].
In the WHI study, in case of EPT, the risk of stroke 
for women who initiated hormone therapy when aged 
younger than 60 years and/or who were within 10 years 
of menopause onset was rare (< 1/1,000) and statisti-
cally insignificant.
In case of ET, if the women initiated hormone ther-
apy at the age of 50–59 years, the risk was reduced 
by 1/100,000 person-year, but for women fewer than 
10 years from menopause onset, there was a trend of 
increase in the risk by 1/100,000 person-year. These 
results were inconsistent but were not statistically insig-
nificant.
On the other hand, for women who initiate HT when 
aged above 60 years and/or who are more than 10 years 
from menopause onset, hormone therapy increases 
the risk of stroke. The risk differs depending on the 
age range; in case of EPT, the HR was 1.45 (95% CI, 
1.00–2.11) for women in their 60s and 1.22 (95% CI, 
0.84–1.79) for those in their 70s; hence, there was no 
statistical significance. In case of ET, HR was 1.55 (95% 
CI, 1.10–2.16) for women in their 60s and 1.29 (95% 
CI, 0.90–1.86) for those in their 70s.
In the results of a long-term follow-up observation up 
to 13 years after completing the WHI study, stroke risks 
did not differ significantly between women formerly 
assigned to hormones and women formerly assigned to 
placebo, and there was no statistical evidence that risks 
differed based on age or timing [81].
Based on the results of observational studies, lower-
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dose oral hormone therapy and lower-dose transder-
mal therapy has less effect on the risk of stroke [82]. 
The increased risk of stroke due to hormone therapy 
may be limited to ischemic stroke and has no effect on 
hemorrhagic stroke.
Based on Korean epidemiology and the data from 
the National Statistical Office (2017), cerebrovascular 
disease is the third highest cause of death in both gen-
ders and the mortality rate by cerebrovascular diseases 
in women is 46.1 deaths every 100,000 people. In the 
national statistics released by the Korean Stroke Society 
in 2018, ischemic cerebral stroke constituted 76.3% and 
hemorrhagic cerebral stroke constituted 23.4% of the 
total cerebrovascular diseases (change order) [83]. The 
stroke incidence in 2013 was similar to that in 2004, 
but the stroke mortality is declining. 
Key points: Cerebral stroke
1.  The risk of stroke in younger postmenopausal 
women is rare, and a meta-analysis including a 
WHI study found no increased risk of stroke in 
women aged younger than 60 years or who were 
fewer than 10 years from menopausal onset.
2.  The risk of cerebral stroke differs depending 
on the age range and MHT increases the risk of 
ischemic stroke in women aged above 60 years.
3.  Lower-dose oral hormone therapy or transder-
mal hormone therapy could relatively reduce the 
risk of stroke.
7. Venous thromboembolism
Venous thromboembolism has an annual disease fre-
quency of 5.4 diseases per 100,000 adult populations 
in Europe and the US regardless of gender. With an 
increase in age, some coagulation factors and activation 
increase, leading to an increase in the risk of thrombo-
sis; however, this is rarely observed before the age of 60 
years [84]. In case of women, it occurs in 1–2 women 
per 1,000 women annually. The risk factors of venous 
thromboembolism include age, obesity, personal his-
tory of thrombosis and genetic thrombophilia [85]. 
In general, a lower frequency of venous thromboem-
bolism is observed in Asian women than in Western 
women [86].
In the U.S. Preventive Services Task Force (USPSTF) 
study, in which a meta-analysis was conducted with the 
WHI study, HERS study, and other references, the risk 
of venous thromboembolism due to hormone therapy 
approximately doubled and the risk was higher during 
the first year of oral estrogen use, with or without pro-
gestogen (Table 1) [87-89].
The absolute risk of VTE was significantly increased 
in women initiating hormone therapy more than 10 
years from menopause onset [75]. In the WHI study, 
based on the analysis according to age, use of ET in 
women aged 50–59 years showed no significant in-
crease in the risk. Because oral estrogen increases the 
activity of thrombin while reducing the activity of plas-
min and has a higher thrombus tendency than that of 
transdermal estrogen, the use of transdermal estrogen 
could be better in case of women having a medical 
history or risk factors of venous thromboembolism 
[1,22,90]. Transdermal estrogen could be a better op-
tion for patients with diabetes, high blood pressure, and 
other risk factors of cardiovascular systems because it 
does not go through liver metabolism, thus leading to 
less stimulation of the synthesis of SHBG [87].
Regarding the risk of venous thromboembolism de-
pending on the type of estrogen there is an opinion that 
CEE use was associated with a higher risk of incident 
VTE than estradiol use [75,90]. The risk of VTE may 
be affected by the type of progestogen, MPA may be as-
sociated with greater risk of venous thromboembolism. 
However, micronized progesterone may be safe with 
thrombotic risk.
The risk of VTE was higher in users of oral estrogen 
plus progestogen than oral estrogen therapy alone 
[70,85,89]. According to the WHI study, hormone ther-
apy for women with factor V Leiden mutation increases 
the relative risk of venous thromboembolism to 6.69 
compared with that for women without any mutations 
who do not receive any hormone therapy. For women 
with a body mass index of more than 25, EPT signifi-
cantly increases the risk of venous thromboembolism 
[91].
Based on the review of domestic references, the in-
cidence of VTE is lower in Asian population than in 
Western populations. There was no factor V Leiden 
mutation reported in Korean subjects at high risk for 
Table 1. Relative risk of venous thromboembolism (VTE) in hormone 
therapy users (RR or HR with 95% CI)
Outcome USPSTF WHI HERS
Outcome USPSTF WHI HERS 
VTE overall 2.14 (1.64–2.81) 2.11 (1.26–3.55) 2.06 (1.26–3.36)
VTE first year 3.49 (2.33–5.59) 3.6 (no CI) 3.28 (1.07–10.1)
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thrombophilia. There was one case of venous thrombo-
embolism after using MHT in South Korea, but even in 
this case, there was no factor V Leiden mutation [92].
Key points: Venous thromboembolism
1.  MHT increases the risk of venous thromboem-
bolism. Particularly, the risk of VTE increases 
with age and increases in women initiating hor-
mone therapy more than 10 years from meno-
pausal onset.
2.  The risk of venous thromboembolism increases 
in the first 1 to 2 years of MHT and decreases 
afterwards.
3.  Estrogen therapy has a lower risk of venous 
thromboembolism than EPT, and if used in the 
early postmenopausal period, the risk of venous 
thromboembolism does not increase.
4.  Oral estrogen therapy is banned for patients with 
anamnesis of venous thromboembolism, and 
they must use transdermal estrogen.
5.  The occurrence of venous thromboembolism in 
Asian women is very low, and there has been no 
report of factor V Leiden mutation in South Ko-
rea.
8. Breast cancer
There have been controversies regarding the associa-
tion between MHT and breast cancer. Different results 
are being reported according to the forms and types 
of hormones such as ET, EPT, and CEE–bazedoxifene, 
dose, starting date of medication, period, and indi-
vidual characteristics [93-98]. According to a recent 
randomized controlled study on MHT and occurrence 
of breast cancer and the consultation instructions by 
British Menopause Society, ET did not increase breast 
cancer, whereas EPT showed a tendency of significant 
increase in breast cancer [93,99].
Based on a 5.6-year observation in the WHI study, the 
EPT group showed an increase in the risk of infiltrative 
breast cancer by approximately 1.24 times (absolute 
risk: annual increase of nine cases per 100,000 people), 
and the increase of the risk was observed from the third 
year of MHT [100]. However, the increase of breast 
cancer was limited to women with a history of having 
received MHT prior to participating in the WHI study, 
and in case of women with such histories, the increase 
did not occur until the seventh year and the increase 
of breast cancer was not observed even during the 11-
year follow-up observation period [101,102]. In case 
of ET, based on the 7.2-year observation, there was a 
tendency of reduction of the risk of breast cancer (ab-
solute risk: annual reduction of seven cases per 100,000 
people), even though it was not statistically significant. 
In particular, in case of women without any history 
of receiving MHT or those who received it for more 
than 80% continuously, there was a statistically sig-
nificant reduction (33%–35% reduction). In the 13.2-
year cumulative follow-up observation after stopping 
ET, the occurrence of breast cancer was significantly 
reduced by 21% [81]. Moreover, in the extended study 
(on average, 5.9-year of use, 11.8-year of observation) 
conducted after the WHI study targeting women who 
wanted continuous single use of estrogen therapy, the 
risk of breast cancer significantly decreased [103,104]. 
According to the Nurse Health Study, there was no sig-
nificant increase in the risk of breast cancer in the ET 
group until the 15th year [105].
There is no reliable research finding about whether 
low-dose estrogen–progestogen combination therapy 
increases the risk of breast cancer. In case of long-term 
use of progestogen, there has been a report about the 
possibility of increasing the frequency of breast cancer 
occurrence. However, according to the E3N-EPIC co-
hort study conducted in France, there is a report about 
how natural progesterone use would not increase the 
risk of breast cancer. Therefore, the risk of breast can-
cer is expected to differ depending on the progestogen 
medicine [106].
In a small number of observational studies, MHT did 
not increase the risk of breast cancer in women with a 
family history of breast cancer or who received ovari-
otomy and have BRCA 1/2 [107-110]. Thus, because 
MHT could increase recurrence in breast cancer pa-
tients, it is not advised [111]. However, in case of low-
dose vaginal ET, it could be considered as an effective 
therapy after trying non-hormonal therapy when suf-
fering from urinogenital atrophy due to minimal sys-
temic absorption [112].
However, difference of Korean epidemiology from 
western epidemiology must be considered when indi-
cating the association between breast cancer and MHT 
after reaching menopause. The risk of occurrence of 
breast cancer in American women begins from the 
age of 15 years and increases from the age of 40–49 
years, and the highest rate of occurrence is observed 
at the age of 70–74 years, which gradually decreases 
afterward. In case of South Korea, the middle age at the 
79
The 2020 Menopausal Hormone Therapy Guidelines
point of diagnosis is 50 years and 40s is the age range 
in which the highest number of breast cancer cases oc-
curred. The order of frequency of disease as per age is 
as follows: 40s, 50s, 60s, 30s, and 70s [113-115]. Com-
pared with the past results, there is a general tendency 
of increase in the occurrence age, and from 2010, an in-
crease in the number of patients in their 50s diagnosed 
with breast cancer was observed. Occurrence of breast 
cancer keeps increasing but is still relatively low as it is 
1/2–1/3 of the occurrence in the west. In case of west-
ern women, the frequency of breast cancer increases 
as age increases, whereas in case of Korean women, 
the frequency increases until early 50s, then gradually 
decreases afterward [113-115]. The ratio of breast can-
cer before menopause is significantly higher than that 
in the west. There is a high occurrence rate in young 
patients in their 40s, and patients under 40s constitute 
about 13% of the cases, which is more than two times 
higher than that in the west [113]. The occurrence rate 
in American women is 126.4 cases per 100,000 people, 
whereas the mortality rate due to breast cancer is 20 
cases per 100,000 people. The frequency in South Korea 
is 75.1 cases (2015), and the mortality rate is 9.6 cases 
(2016), which is a significantly low occurrence rate and 
mortality rate, therefore showing a very different aspect 
from an epidemiological perspective [113-115].
Key points: Breast cancer
1.  After using EPT for an average period of 5.6 
years, the risk of breast cancer increased but for 
women who were starting MHT for the first 
time, the risk of breast cancer did not increase 
until the 7th year.
2.  In case of ET, the risk of breast cancer reduced 
after using it for 7.2 years and significantly re-
duced after 13.2 years of follow-up observation.
3.  MHT is not advised for breast cancer patients.
4.  As South Korean breast cancer epidemiology is 
very different from that of the US, it is impracti-
cal to apply the research findings of the US ex-
actly to the cases in South Korea.
9. Ovarian cancer, endometrial cancer, 
colorectal cancer, and lung cancer
9-1. Ovarian cancer
Ovarian cancer, the 9th most common type of cancer 
in the west, occurs every 27 cases per 100,000 people 
among women aged above 50 years, and the average age 
at the point of diagnosis is approximately 64 years with 
more than 80% women aged above 50 years. Moreover, 
in South Korea, the number of ovarian cancer patients 
shows a trend of continuous increase (change of loca-
tion) [116].
Until now, there is no reliable data that could confirm 
the association between MHT and the occurrence of 
ovarian cancer. According to the 5.6-year observa-
tion in the WHI study, which is the only randomized 
controlled study that could analyze the association 
between ovarian cancer and MHT, the risk of ovarian 
cancer did not significantly increase in both ET group 
and EP group (HR, 1.24; 95% CI, 0.83–1.87, HR 1.41; 
95% CI, 0.75–2.66) [117]. However, several observa-
tional studies have reported an increased risk: Nurses’ 
Health Study reported an increased relative risk of 
ovarian cancer by 1.41 times (95% CI, 1.07–1.86) when 
using estrogen for more than 5 years; NIH-AARP Diet 
and Health Study reported an increased relative risk of 
ovarian cancer by 2.15 times (95% CI, 1.30–3.57) when 
using ET for more than 10 years and by 1.68 times (95% 
CI, 1.13–2.49) when using EPT for more than 10 years. 
However, even if MHT increases the risk of ovarian 
cancer, the increase is about 0.8 cases per 10,000 people 
annually, which is considered very rare.
Based on the meta-analysis, in ovarian cancer pa-
tients, MHT does not increase the mortality rate or 
recurrence rate of ovarian cancer, but there is almost no 
data available yet on low-grade serous cancer as well as 
granulosa cell tumor or cancer, which involve positive 
estrogen receptors such as Sertoli–Leydig tumor [118].
Key points: Ovarian cancer
1.  Estrogen–progestogen combination therapy does 
not increase the risk of ovarian cancer.
2.  There are reports showing that long-term estro-
gen therapy increases the risk of epithelial ovar-
ian cancer, but the absolute number is rare as it 
was about 0.7 cases per 1,000 people for 5 years.
9-2. Endometrial cancer
In women with the uterus, administration of estrogen 
alone increases the risk of endometrial cancer in pro-
portion to its dose and duration. Therefore, in the pres-
ence of the uterus, estrogen and progestogen should be 
administered in combination. In the WHI study, the 
continuous EPT combination therapy showed a similar 
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result to the comparative group regarding endometrial 
cancer [117].
According to recent studies, among patients with en-
dometrial cancer, if the patients that belong to endome-
trioid subtypes I and II had excision of the uterus and 
bilateral appendages and the estrogen receptors and 
progesterone receptors tested negative, the recurrence 
rate and mortality rate of endometrial cancer did not 
increase, even when MHT was applied [119]. However, 
even in case of early endometrial cancer, the therapy 
is recommended 5 years after complete recovery. For 
stages III and IV endometrial cancer, clear cell carci-
noma, or serous papillary carcinoma patients, MHT is 
not recommended [120,121].
The incidence of endometrial cancer in Korea has 
rapidly increased, increasing more than 10 times from 
132 cases in 1991 to 1,619 cases in 2009 and reach-
ing 2,404 cases in women in 2015. According to age 
groups, women in their 50s showed the highest inci-
dence at 38.4%, followed by those in their 40s at 25.2% 
and those in their 60s at 17.9%.
Key points: Endometrial cancer
1.  For women with the uterus, estrogen–proges-
togen combination therapy should be adminis-
trated to protect the endometrium.
2.  A sufficient dose of progestogen administered 
for a sufficient period of 12–14 days per month 
leads to little increase in risk of endometrial 
cancer, and continuous administration of com-
bination therapy leads to a reduction in risk of 
endometrial cancer.
3.  MHT may be considered if non-hormonal 
therapy is not effective in early endometrial can-
cer patients with an excised uterus and bilateral 
appendages when they show menopausal symp-
toms.
4.  In case of patients with stages III and IV endo-
metrial cancer or high-risk endometrial cancer, 
non-hormonal therapy should be used to control 
menopause symptoms.
9-3. Colorectal cancer
Observational studies including Nurses’ Health Study 
showed that administration of hormone therapy during 
menopause significantly reduces the risk of colorectal 
cancer [121]. In the WHI study, which is a large-scale 
randomized controlled study, estrogen–progestogen 
combination therapy has been reported to reduce the 
risk of colorectal cancer by 38% when compared with a 
placebo (HR 0.62; 95% CI, 0.43–0.89) [122]. However, 
when the administration stops, the prevention effect 
of colorectal cancer disappears. Individual estrogen 
therapy does not have any effect on invasive colorectal 
cancer or on the mortality rate due to invasive colorec-
tal cancer [123,124].
In Korean women, colorectal cancer is the third high-
est type of cancer in females (10.7%) and occurred 
among 10,846 women in 2015. It occurred most com-
monly among women aged above 65 years. The mortal-
ity rate of colorectal cancer is the second highest after 
that of lung cancer.
Key points: Colorectal cancer
1.  Estrogen–progestogen combination therapy re-
duces the risk of colorectal cancer.
2.  Estrogen therapy does not have any effect on 
colorectal cancer.
3.  Executing MHT with the sole purpose of pre-
venting colorectal cancer is not advised.
9-4. Lung cancer
In the WHI study, both individual estrogen therapy 
and estrogen–progestogen combination therapy did 
not increase the occurrence of lung cancer. However, in 
case of estrogen–progestogen combination therapy, the 
mortality rate due to lung cancer increased, which was 
limited to past or current smokers aged above 60 years. 
The absolute risk was also very low as the increased 
mortality was 4 cases per 10,000 people and individual 
estrogen therapy did not have any effect on the mortal-
ity rate of lung cancer [125].
The IMS claimed that based on the analysis of many 
observational research findings, MHT has a protec-
tive effect against occurrence of lung cancer in patients 
aged less than 60 years. In South Korea, lung cancer is 
the fifth highest type of female cancer (7.2%), which 
affected 7,298 women in 2015 and has the highest mor-
tality rate among female cancers.
Key point: Lung cancer
1.  MHT does not increase the occurrence of lung cancer.
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10. Cognitive function and Alzheimer’s
The WHI memory study (WHIMS), an ancillary 
study to WHI study, reported a significant increase in 
the risk (2.05) of probable dementia in the EPT group 
with women aged above 60 years every year, and the 
risk increased to 1.49 in the ET group, but no statistical 
significance was observed [126,127]. The WHI study of 
cognitive aging, another ancillary study about cognitive 
function, observed a slight improvement in nonverbal 
episodic memory in the EPT group but a reduction in 
verbal episodic memory, although no particular effect 
was observed in the ET group [128]. Another ancillary 
study, the WHIMS-Magnetic Resonance Imaging study 
showed a reduction in the volume of some brain areas, 
especially of the frontal lobe and hippocampus in MHT 
patients compared with the control group [129].
In contrast, according to the findings from the MI-
RAGE study, which compared 426 Alzheimer’s patients 
with patients without Alzheimer’s, the risk of Alzheim-
er’s in the group that received MHT was 30% lower 
than that in the control group for all age groups [130]. 
Similarly in case of the Cache county study, which 
targeted 1,889 women, the risk of Alzheimer’s in the 
MHT group was significantly lower by 0.41 times (95% 
CI, 0.17–0.86) when compared with the control group 
[131]. Such observational research findings showed 
different results from the WHIMS study; this could be 
owing to the effect of difference of age and the starting 
point of MHT (Table 2) [132]. WHIMS’s research tar-
get was women aged above 65 years who had relatively 
increased risk of Alzheimer’s. Thus, the patients diag-
nosed with Alzheimer’s during the study could have 
already well manifested Alzheimer’s symptoms, which 
were not clinically revealed at the starting point of the 
study.
In contrast to WHIMS, in the recently released 
KEEPS study, MHT did not have any effect on memory 
or cognitive function. This could also be because of 
the fact that the study targeted young women who had 
just reached menopause [133]. The “critical window 
hypothesis” refers to a concept that addresses that the 
effect of MHT on cognitive function could differ de-
pending on the time of executing the MHT [134,135]. 
Although the highest improvement effect on cognitive 
function could be expected if MHT is started immedi-
ately at the point of decline in ovarian function due to 
natural menopause or ovariotomy, if MHT is started 
in old women in menopause, it could actually cause a 
harmful effect on cognitive function.
In the Study of Women’s Health Across the Nation 
study, a better recall score was shown in case of start-
ing MHT before the last menstruation, whereas in case 
of starting MHT after the last menstruation, a decline 
in cognitive function was observed [136]. Another ob-
servational study reported that although starting MHT 
at midlife helped prevent cognitive disorder, starting 
MHT during late life caused a negative effect on cogni-
tive function [134]. In the MIRAGE research findings, 
although the risk of Alzheimer’s was reduced by 65% 
for the age range of 50–63 years when using MHT, for 
the age range of 64–71 and 72–89 years such effects 
did not appear and the effect of MHT on Alzheimer’s 
seemed better with younger age [130]. Based on re-
search findings about women with the average age of 74 
years, Zandi et al. [131] also suggested the possibility of 
a period during which MHT influences cognitive func-
tion and reported that in case of MHT administered 
for more than 10 years but currently stopped, the risk 
of Alzheimer’s occurrence was reduced by 83%, and in 
case of MHT administered in the past, the risk of Al-
Table 2. Considerations for discrepant findings between most observational studies on MHT and the WHIMS randomized trials of MHT
Factors Observational studies WHIMS trials
Susceptibility to bias or confounding Large Small
Primary outcome Alzheimer’s disease All-cause dementia
MHT formulation Often CEE; sequential progestin Only CEE; continuous progestin
Menopausal symptoms Common Uncommon
Age at the time of study Variable; usually older Older (65+ years)
Age at MHT exposure Usually younger Older (65+ years)
Timing of MHT initiation Usually close to menopause Remote from menopause
Overall outcomes Generally beneficial Generally detrimental
Adapted from Henderson (2006) [132].  
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zheimer’s occurrence was reduced by 41% [6]. Howev-
er, clinical evidence lacks such “critical window hypoth-
esis” yet [90]. For example, in the WHIMS of Younger 
Women study, which targeted young menopausal 
women with the age range of 50–59 years and analyzed 
the effect of MHT on cognitive function, MHT using 
CEE did not result in improvement of general cognitive 
function regardless of combining with progestin [137].
Recently, the “healthy cell bias hypothesis” is often 
introduced instead of the existing “critical window 
hypothesis” about the difference in the effect of cogni-
tive function regarding the execution time of MHT 
[138,139]. This means that in terms of the effect of 
MHT, the woman’s health is a more important determi-
nant than physiological age. Even an old woman could 
benefit from the use of MHT if her cognitive function 
is “healthy.” However, both hypotheses share a limita-
tion that they were not supported by large-scale ran-
dom blind studies [90].
In case of surgical menopause, as the concentration 
of estrogen rapidly decreases, the effect on cognitive 
function could possibly differ from that in case of 
natural menopause [140,141]. The faster the surgical 
menopause is done, the higher is the risk of Alzheimer’s 
or cognitive disorder [142]. Guidelines from both the 
North American Menopause Society and IMS recom-
mend that estrogen therapy immediately after surgi-
cal menopause could help improve cognitive function 
[22,90].
In several small-scale studies that were conducted in 
1980s–1990s on whether injection of female hormone 
could help improve cognitive function in women with 
Alzheimer’s, improvement of cognitive function was 
reported when the female hormone was administered 
to the Alzheimer’s patient [143-145]. However, the 
positive effect in the observational study could be be-
cause of the fact that the subjects were relatively young 
women and recall bias might have occurred. In the re-
ported random double-blind study in 2000, no change 
in cognitive function was observed when administering 
individual female MHT for 1 year targeting 120 women 
with Alzheimer’s who had undergone hysterectomy due 
to medical history [146].
Korean epidemiology reported that 4.2% of the el-
derly aged above 65 years has Alzheimer’s. In the study 
that targeted South Korean Alzheimer’s patients, MHT 
was administered for 1 year, and it was reported that 
the MMSE score did not decline, although it showed 
similar effects to the representative Alzheimer’s medi-
cine, tacrine, regarding cognitive function, and that 
the MHT improved the daily activity capacity. Thus, a 
positive effect of MHT was reported [147].
Key points: Cognitive function and Alzheimer’s
1.  If MHT is started in early menopausal women, 
a prevention effect against the reduction of cog-
nitive function could be expected although the 
evidence from randomized controlled studies is 
lacking.
2.  Executing MHT with the sole purpose of pre-
venting worsening or treatment of current cogni-
tive function is not advised.
11. Depression
The prevalence rate of major depressive disorder 
in women of age 50 and over is 4.0%–5.4% in South 
Korea, which is about three times higher than that 
in men (1.3%–2.4%) [148]. Most women (more than 
85%) in menopausal transition do not experience a 
new onset of depression, and the risk of depression is 
similar to that before or after menopause. However, 
hormonal changes and vasomotor symptoms can lead 
to new depressive symptoms and the risk of developing 
depression could increase during menopausal transi-
tion or early menopause [149,150]. Although it has 
been shown that estrogen therapy has a positive effect 
on mood disorder in women who had surgical meno-
pause, even without menopausal symptoms [151], it re-
mains unclear whether MHT has a beneficial effect on 
mood disorder in women who are not diagnosed with 
depression [22,152].
Until now, there have been very few randomized 
controlled studies on MHT in middle-aged women 
with depression. Although some studies reported that 
short-term estrogen therapy could alleviate symptoms 
of depression during menopausal transition in women 
with depression [153,154], most studies failed to find 
a positive effect of MHT on depression in older meno-
pausal women [155-157]. In women who experienced 
improvement in depressive symptoms with MHT, 
symptoms could get worse after stopping MHT [158].
Addition of progestogen could negatively affect mood 
in women with a past history of depression, premen-
strual syndrome, or premenstrual dysphoric disorder 
[159]. The effect of progestogen on the central nervous 
system could differ depending on the ratio of estrogen 
and progestogen [160].
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Key points: Depression
1.  MHT could show a positive effect, although 
limited, on affective disorder during menopausal 
transition.
2.  In women who experience improvement in de-
pressive symptoms through MHT, symptoms 
could easily worsen when treatment is stopped.
3.  There is lack of clinical evidence supporting the 
use of MHT for treatment of depression.
12. Osteoporosis
12-1. Bone density
The standard dose of MHT increases bone density by 
inhibiting bone resorption and reducing bone remodel-
ing process. The response of bone density to estrogen is 
dose-dependent. In the Postmenopausal Estrogen/Pro-
gestin Interventions trial, bone density increased at the 
lumbar spine and femur in women who received ET or 
EPT (0.625 mg CEE/MPA or micronized progesterone) 
for 3 years compared with the control group [161]. In 
the WHI study, bone density at the lumbar spine and 
femur increased by 4.5% and 3.7%, respectively, with 
the standard-dose EPT (0.625 mg CEE + 2.5 mg MPA) 
compared with the control group [162].
In a meta-analysis, 2 years of oral MHT increased 
bone density at the lumbar spine (6.8%) and femur 
(4.1%) compared with the control group [163]. Bone 
density significantly increased at both the lumbar spine 
and femur with low-dose ET or EPT (oral CEE 0.3 
mg, 17beta-estradiol 0.25 mg, 17beta-estradiol 0.014 
mg patch) in young (average age: 51–52 years) and old 
(average age: 67–74 years) postmenopausal women 
[164,165].
12-2. Fracture
In the National Osteoporosis Risk Assessment 
(NORA) study, the risk of new fractures significantly 
decreased when evaluating 200,160 postmenopausal 
women using MHT with no history of osteoporosis. In 
current ET or EPT users, the risk of clinical fracture at 
the femur, spine, humerus, wrist, or rib was reduced, 
although this beneficial effect did not persist after stop-
ping MHT for 5 years. In particular, the risk of fracture 
at the femur when women stopped MHT for 5 years 
was similar to that with no treatment [166].
In the WHI study, the risk of facture significantly 
decreased by 33% at the lumbar spine and 35% at the 
femur using EPT and by 38% at the lumbar spine and 
39% at the femur using ET. This protective effect rapid-
ly disappeared after stopping MHT, and the long-term 
follow-up study of WHI reported that the ET group 
showed a continued reduction effect of all fractures 
after stopping therapy, whereas the EPT group showed 
no reduction in all fractures [81].
Most (82%) menopausal women with fractures in the 
NORA study were reported to have osteopenia with a T 
score above −2.5, but even though the frequency of fe-
mur fracture was the highest in the study, only 6.4% of 
the patients had a T score below −2.5 [166]. Therefore, 
MHT is also necessary to prevent bone loss or fracture 
in women with osteopenia.
No difference was found between the continuous and 
cyclic use of progestogen, and no effect has been prov-
en to reduce the risk of fractures using low- and ultra-
low-dose estrogen therapy.
NAMS reported that MHT prevents menopause-
related bone loss and reduces osteoporotic fractures 
including those of the spine and femur in the low-risk 
group. MHT is an appropriate first-line treatment in 
menopausal women aged less than 60 years with an in-
creased risk of fracture, but MHT is not recommended 
solely for the prevention of fracture in women aged 
above 60 years. MHT also prevents bone loss in women 
with premature ovarian failure [90].
The prevalence rate of osteoporosis in individuals 
aged above 50 years was 7.5% in men and 35.5% in 
women from the Korean National Health and Nutrition 
Examination Survey in 2008–2009. The incidence rate 
of femur fracture increased from 99.6 cases per 100,000 
in men and 209.9 cases per 100,000 in women in 2008 
to 110.5 cases per 100,000 in men and 243.1 cases per 
100,000 in women in 2012 from the data from National 
Health Insurance Service [167]. In the multi-center ret-
rospective observational study conducted by the Kore-
an Society of Menopause in 2012, patients whose bone 
density was reduced after the first year of MHT showed 
increased bone density in the second year of MHT. In 
contrast, patients whose bone density was remarkably 
increased after the first year of MHT demonstrated 
relatively lower or decreased bone density in the second 
year of MHT. This finding was similar across EPT, ET, 
and tibolone users. It was concluded that even if bone 
density is temporarily reduced after MHT, it should not 
be the only reason for changing therapy [168].
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Key points: Osteoporosis
1.  Because MHT prevents menopause-related 
bone loss and reduces the risk of fracture, it is 
an appropriate therapy for the prevention and 
treatment of osteoporosis in young menopausal 
women aged less than 60 years or those with less 
than 10 years since menopause.
2.  Bone protective effect is rapidly lost after stop-
ping MHT.
3.  Standard dose of MHT reduces the femur, ver-
tebral, and non-vertebral fractures in women 
without osteoporosis.
4.  Efficacy of reducing the risk of fracture has not 
been proven in low- and ultra-low-dose estrogen 
therapy.
5.  MHT is necessary for women with premature 
ovarian insufficiency (premature menopause) or 
osteopenia to prevent bone loss.
13. Sarcopenia
The prevalence rate of sarcopenia in community-
dwelling older adults was 35.3% in women and 13.4% 
in men aged above 65 years from the Korean longi-
tudinal study on health and aging. In another epide-
miological study targeting the elderly in the Gangbuk 
district in Seoul, the prevalence rate of sarcopenia was 
6.3% in men and 4.1% in women [169-171]. In addi-
tion, according to the cumulative data of more than 
10 years from the Korean National Health and Nutri-
tion Examination Study, 19.5% of women in their 50s, 
16.6% of women in their 60s, 23.7% of women in their 
70s, and 30.8% of women in their 80s were reported to 
have sarcopenia [172-174].
Several studies showed that MHT can preserve mus-
cle strength and recover rapid loss of muscle strength. 
Muscle strength increased up to 24 months when using 
MHT, and the maximal voluntary force also increased 
in the MHT group in contrast to a decrease in the con-
trol group. Likewise, vertical jumping height and maxi-
mal walking speed were significantly higher with MHT 
in monozygotic twins. When combining MHT and ex-
ercise, the effect of improving the muscle tone, muscle 
mass, and muscle strength was enhanced. These results 
suggest that MHT can help increase muscle strength 
and prevent muscle contraction and movement limita-
tion; furthermore, a meta-analysis showed that MHT 
helps improve muscle intensity. However, this benefi-
cial effect was not found when MHT was used in older 
women aged above 60 years or when used for less than 
6 months [175,176].
In contrast to the consistent effect being reported re-
garding muscle strength, the effect of MHT on muscle 
mass remains controversial. In the WHI study, a pres-
ervation effect of body mass except fat was observed 
during the first 3 years of MHT, but this effect was 
reduced and disappeared during the 3 years afterward. 
This implies that the effect of MHT can depend on age 
[177].
In summary, MHT alone or combined with exercise 
could increase muscle mass, alleviate its reduction, and 
improve muscle function and regeneration of skeletal 
muscle. However, as most studies are small with differ-
ent age, health condition, and exercise program, the in-
terpretation of results could be affected. Therefore, ad-
ditional studies are needed to draw a clear conclusion. 
On the other hand, although there is a lack of studies, 
plant hormones such as isoflavone are considered to 
have no effect on sarcopenia [178].
Key points: Sarcopenia
1.  MHT, particularly when combined with exercise, 
seems to be effective in increasing muscle mass, 
alleviating its reduction, and improving muscle 
function and muscle strength.
2.  There is a lack of evidence regarding the use of 
MHT primarily for the purpose of treating and 
preventing sarcopenia.
14. Gallbladder disease and migraine
Gallstone (or gallbladder disease) occurs in 10%–15% 
cases in the US and increases by 1 million people annu-
ally. The occurrence of gallbladder disease has a close 
association with estrogen therapy. In South Korea, the 
frequency of gallstones is about 2%–4% and the num-
ber of patients with gallstones has increased by 49% 
from 129,226 people in 2014 to 192,551 in 2018, ac-
cording to the data from the Health Insurance Review 
and Assessment Service. This is because of the western-
ization of eating habits. Gallstones are more common 
among women than among men. In South Korea, it is 
reported to occur 1.1 times more frequently in women 
than in men, and the frequency increases in both gen-
ders from 40 to 50 years of age [179].
Estrogen increases the risk of gallstone by accelerat-
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ing the increase of secretion and saturation of choles-
terol within the gallbladder, which leads to increased 
concentration of cholesterol and reduced activity of 
the gallbladder. Apart from MHT, factors such as use 
of combined oral contraceptive and pregnancy also 
increase the risk of cholesterol gallstones [180]. In the 
WHI study, the relative risk of cholecystitis and chole-
cystectomy was increased in case of both ET (79%) and 
EPT (61%) [181]. However, MHT was not associated 
with other bile duct surgeries. In a meta-analysis re-
garding the occurrence of cholecystitis, the relative risk 
increased to 1.8 in women who used MHT for less than 
5 years, whereas it increased to 2.5 in women who used 
MHT for more than 5 years. The frequency of chole-
cystectomy was lower with non-oral MHT than with 
oral MHT [11,90].
There is a lack of data on the relationship between 
MHT and migraine, and evidence for banning the use 
of MHT merely due to migraines is very rare.
Key points:  Gallbladder disease and migraine
1.  ET or EPT increases the risk of gallbladder dis-
eases.
2.  Careful monitoring of gallbladder disease is re-
quired in women using oral MHT.
3.  Non-oral MHT is recommended for women 
with gallbladder disease.
4.  Because there is a lack of data on the relation-
ship between MHT and migraine, it cannot be 
concluded that migraine is a contraindication for 
MHT.
15. Cautions for HT
15-1. Indication of progestogen
For women with the uterus intact, estrogen must be 
administered together with progestogen to reduce the 
risk of endometrial hyperplasia and cancer. For women 
with no uterus, progestogen may not be administered, 
but if there is a history of endometriosis or a partial 
uterus left when performing hysterectomy and in case 
of an endometrioid type of ovarian cancer, administra-
tion of progestogen is required. In case of receiving 
vaginal estrogen therapy due to vaginal atrophy or re-
ceiving minimum dose transdermal estrogen therapy 
to prevent bone disappearance, progestogen may not be 
administered, but the long-term safety of progestogen 
administration for more than 1 year remains unclear 
[90,159].
15-2. Route of administration
The route of administration can be oral and non-oral, 
and non-oral administration is known to have no first-
pass effect on the liver and almost no effect on SHBG, 
blood pressure, neutral fat, and C-reactive protein level 
when compared with oral administration. In case of 
having only symptoms of vaginal atrophy and vaginal 
dryness, topical vaginal estrogen is recommended, 
whereas for women with a high risk of venous throm-
boembolism and high neutral fats as well as for obese 
women with metabolic syndrome, transdermal therapy 
should be selected first. For women with smoking hab-
its and high blood pressure, transdermal therapy is also 
recommended [90,159].
15-3. Timing of initiation
It is better to start MHT immediately once symptoms 
appear before or after menopause. If premature hypoes-
trogenism or early menopause (menopause under 45 
years of age) is diagnosed, it is recommended to start 
MHT regardless of whether symptoms of menopause 
are present [182].
15-4. Duration of MHT
Based on the results of previous research, it is not yet 
possible to provide clear instructions regarding the 
duration of MHT. However, there is no need to impose 
a limit on the duration of MHT as long as an effective 
minimum dose is used, if women are well aware of 
the potential benefits and risks, and a regular clinical 
follow-up observation is accompanied. Particularly 
for healthy women aged less than 60 years or those 
who have started MHT within 10 years of reaching 
menopause, if there is no occurrence of new diseases, 
it is safe to continue MHT. There is no need to discon-
tinue daily MHT at 60–65 years of age, and evaluat-
ing comorbidity, trying to temporarily discontinue or 
reduce hormone therapy, or eventually switching to 
safer transdermal therapy could be considered instead 
[90,159].
When determining whether to continue MHT, the 
following factors should be considered: first, the posi-
tive effect of MHT for the treatment of continuous 
vasomotor symptoms, reduction of bone density, pre-
vention of fracture, reduction of colorectal cancer, and 
prevention and treatment of symptoms of urinogenital 
diseases; second, consideration of the potential risk of 
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breast cancer, which could increase as the duration of 
MHT increases, as well as thrombotic events (VTE, 
PE, and stroke). Additionally, although starting MHT 
when almost reaching menopause could help reduce 
the mortality related to coronary artery disease and 
other diseases, in women starting MHT who have al-
ready passed 10 years of menopause, especially more 
than 20 years after menopause or are above 60 years of 
age, it must be noted that the absolute degree of risk of 
thrombotic events (VTE, PE, and stroke) and coronary 
artery disease is higher than that in women who have 
started MHT at the beginning of menopause [90,159].
Premature hypoestrogenism or early menopause does 
not have a high risk of breast cancer due to MHT, and 
in this case, diabetes and coronary artery disease could 
prematurely occur due to early menopause. Therefore, 
receiving MHT at least until the mean age of natural 
menopause (50–52 years) is advised [182].
15-5. Methods to stop MHT
There is no significant difference in the recurrence 
rate of vasomotor symptoms depending on whether 
MHT is gradually or abruptly discontinued. However, 
there is still no consensus on which is a better method 
to discontinue MHT [90,159].
15-6. Bioidentical MHT
Bioidentical MHT may be administered in excessive 
or very low doses, with no guidelines established for 
administration and routine tests, including blood tests. 
Moreover, there is a lack of evidence regarding its safety 
and effects [90,159].
15-7. Complementary therapy, non-pharmacolog-
ical, lifestyle intervention
Reports claim that methods such as cognitive behav-
ioral therapy, mindfulness training, hypnosis, and stel-
late ganglion blockade could help alleviate VMS, but 
there is a lack of evidence of the effects and safety of 
complementary therapy [90,159].
15-8. Other medication
Using DHEA topically everyday may be effective in 
treating GSM [90]. Ospemifene, an optional estrogen 
receptor agent, has been approved for use in treating 
GSM and severe dyspareunia in women who have dif-
ficulties using estrogen [90,159].
Key points: Cautions for HT
1.  For women with the uterus intact, estrogen must 
be administered together with progestogen to 
reduce the risk of endometrial hyperplasia and 
cancer.
2.  It is better to start MHT immediately once symp-
toms appear before or after menopause.
3.  There is no need to impose a limit on the dura-
tion of MHT as long as an effective minimum 
dose is used, if women are well aware of the po-
tential benefits and risks, and a regular clinical 
follow-up observation is accompanied.
4.  Bioidentical MHT may be administered in ex-
cessive or very low doses, with no guidelines 
established for administration and routine tests, 
including blood tests.
5.  There is a lack of evidence of the effects and 
safety of complementary therapy.
6.  DHEA and ospemifene may be effective in treat-
ing GSM.
16. Tibolone therapy
Tibolone, a 19-nortestosterone derivative as well as 
a combined steroid, shows a biological effect and ac-
tion via three metabolites. After intake, tibolone is 
transformed into Δ4-tibolone in the liver and stomach, 
which has the characteristics of androgen, progestogen, 
and estrogen metabolite (3α-,3β-hydroxytibolone). It 
plays a similar role as estrogen via the estrogen receptor 
and shows effects of alleviating menopausal symptoms 
and preventing bone loss while not irritating breast and 
endometrial tissue by showing tissue selectivity due to 
the changes in enzyme activation. Tibolone is consid-
ered safe against breast cancer by selectively reducing 
estrogen levels in breast tissue. Tibolone does not have 
biological activation in itself, but as its metabolites 
show particular medicinal effects according to human 
tissue, it is categorized as a selective tissue estrogen ac-
tivity regulator.
16-1. Effects on menopausal symptoms
Tibolone shows an estrogen action effect, which is ef-
fective for treating menopausal symptoms. Tibolone is 
effective in alleviating symptoms such as fatigue, head-
ache, insomnia, and perspiration.
1) VMS
The optimal daily dose of tibolone for treating VMS is 
2.5 mg, and it shows a significant effect within 4 weeks 
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of administration and shows a maximum effect after 12 
weeks of administration [183].
When taking more than 1.25 mg over a period of 12 
weeks, 86% of participants experienced improvement 
of hot flush [183]. The results of the Tolerability Trial 
comparing Activelle with Livial study, which com-
pared the effect on vaginal atrophy, VMS, and abnor-
mal vaginal bleeding by randomly allocating 2.5 mg 
tibolone or low-dose MHT (E2/NETA, 1 mg/0.5 mg) 
to menopausal women with a mean age of 55 years, 
showed that VMS and vaginal atrophy were improved 
similarly in both groups when compared with the early 
phase of therapy [184]. In addition, the frequency of 
abnormal vaginal bleeding was significantly low in the 
group treated with tibolone during the first 3 months 
of therapy. In addition, the frequency of breast pain 
was significantly low in the group treated with tibolone 
when compared with the E2/NETA group.
2) QoL
In a randomized controlled trial (RCT) that compared 
a placebo, 17β estradiol (2 mg), and tibolone targeting 
women with surgical menopause, the group treated 
with tibolone presented a better effect in alleviating 
VMS as well as other symptoms such as mood disorder, 
insomnia, concentration disorder, fatigue or loss of en-
ergy, apathy, and migraine [185].
The International Tibolone Consensus Group in 2005 
and Asia Pacific Tibolone Consensus Group in 2010 
implied that tibolone is a treatment for menopausal 
women with mood changes as well as VMS because it 
shows a positive effect in treating mood disorder, sexu-
al function, and sleep and causes less abnormal vaginal 
bleeding and less discomfort to the breast [185,186].
Based on the analysis of WHQ scores, low-dose MHT 
(E2/NETA, 1 mg/0.5 mg) and tibolone were reported 
to improve QoL, and tibolone mostly improved sexual 
function and showed good results in treating VMS 
[187]. Tibolone increased muscle mass and reduced the 
waist–hip ratio in menopausal women [188,189].
In an RCT that evaluated the effectiveness of medi-
cine after administering tibolone (2.5 mg) or a placebo 
for 12 months to menopausal women with a mean age 
of 54 years, the muscle strength, which was evaluated 
by assessing the hand grip strength in the 12th month, 
in the group administered tibolone was improved com-
pared with that in the control group [190].
3) GSM
Tibolone improves GSM, and women who received 
tibolone therapy experienced significant improvement 
of vaginal dryness, dyspareunia, and urinary symptoms 
[191].
4) Sexual function
Tibolone has the advantage of increasing libido by in-
creasing the bioavailability of testosterone through the 
reduction of the direct androgen effect of Δ4-isomer 
and SHBG [192].
16-2. Osteoporosis
In the STEP RCT, which aimed to study the effect of 
tibolone on osteopenia and compared bone density af-
ter administering tibolone (1.25 mg) and raloxifene (60 
mg) to menopausal women aged 60–79 years with os-
teopenia for 2 years, bone density in the tibolone group 
was significantly increased in both the lumbar spine 
and femur [193].
In the Long-Term Intervention on Fractures with 
Tibolone (LIFT) study, tibolone (1.25 mg) reduced 
vertebral fracture by 45% and the risk of non-vertebral 
fracture by 26% [194].
16-3. Cardiovascular disorders
When taking tibolone, high-density lipoprotein 
(HDL) cholesterol is reduced by 20%, total cholesterol 
by 10%, and triglycerides by 20%, and low-density li-
poprotein (LDL) cholesterol is also reduced. Moreover, 
tibolone is effective considering the fact that it reduces 
anthogenesis and the acidity of LDL [195].
In the Livial Intervention following breast cancer: 
Efficacy, Recurrence, And Tolerability Endpoints (LIB-
ERATE) study, which targeted patients with breast 
cancer, the tibolone group did not show an increase 
in the incidence of stroke, venous thromboembolism, 
and coronary artery disease compared with the placebo 
group [196].
In the LIFT study, which targeted women aged above 
60 years with a risk of diabetes, the group administered 
tibolone experienced an increased incidence of cerebral 
stroke, but no significant difference was observed for 
venous thromboembolism and coronary artery disease 
[194]. The IMS also mentions that tibolone increases 
the risk of stroke in patients aged above 60 years but 
does not increase the incidence of venous thromboem-
bolism [197]. However, there has been no large-scale 
prospective study with the purpose of examining the 
occurrence of cardiovascular disorder related to tibo-
lone.
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Tibolone does not increase the breast density in mam-
mography and causes less breast pain than estrogen–
progestogen combination therapy. In the LIFT study, 
tibolone (1.25 mg) reduced the risk of invasive breast 
cancer [194].
In the LIBERATE study, the risk of breast cancer re-
currence was assessed in a clinical double-blind study 
of tibolone that compared the placebo group and pa-
tients who had undergone breast cancer surgery and 
had VMS [196].
Breast cancer was found to recur in 15.2% of patients 
in the tibolone treatment groups (237 of 1,556 patients) 
and in 10.7% of patients (165 out of 1,542 people) in 
the placebo group, and a 1.4-fold increase in the inci-
dence of breast cancer was observed when taking tibo-
lone. Therefore, tibolone should not be used in patients 
with breast cancer.
2) Endometrial cancer and colorectal cancer
Tibolone is associated with a lower incidence of irreg-
ular abnormal vaginal bleeding compared with estro-
gen–progestogen combination therapy [198]. Because 
it suppresses endometrial proliferation and estrogen 
activation, progestogen does not need to be added.
According to the results of the Tibolone Histology of 
the Endometrium and Breast Endpoints Study, tibolone 
does not cause endometrial proliferation or endome-
trial cancer [199]. In the LIFT study, tibolone (1.25 mg) 
reduced the risk of colorectal cancer by 69% [194].
In South Korea, no studies have assessed cardiovas-
cular disease, breast cancer, and fractures, but some 
studies have assessed blood lipids and bone density. 
According to the results of a research on blood lipids, 
tibolone reduces neutral fats while reducing HDL cho-
lesterol compared with MHT [200]. Tibolone gener-
ally showed a positive effect on bone density, and after 
comparing the effects of therapy for 1 year, an increased 
bone density of the lumbar, which is similar to that 
with MHT, was reported 42. Furthermore, tibolone us-
ers who had undergone surgical treatment for epithelial 
ovarian cancer and 33 tibolone non-users were retro-
spectively examined [201]. There was no evidence that 
tibolone negatively affects the overall survival rate as 
well as the survival-free rate of patients with epithelial 
ovarian cancer. Furthermore, in a study that compared 
68 tibolone users who had received surgical treatment 
for endometrial cancer and the same number of non-
users, tibolone did not show any harmful effects in the 
prognosis of the patients with endometrial cancer [202].
Key points:  Tibolone therapy
1.  Tibolone is effective in alleviating menopausal 
symptoms such as hot flush, VMS, and GSM. 
2.  Tibolone is associated with a lower incidence of 
abnormal vaginal bleeding as well as decreased 
breast density in mammography and reduced 
breast pain compared with estrogen–progesto-
gen combination therapy. 
3.  Tibolone could be used relatively effectively for 
treating sexual dysfunction.
4.  Tibolone could be effectively used for other 
symptoms such as mood disorder, sleep disorder, 
concentration disorder, and fatigue. 
5.  Tibolone increases bone density and reduces 
vertebral fracture and non-vertebral fracture. 
6.  Tibolone does not increase invasive breast cancer 
and endometrial cancer, but when used for pa-
tients with breast cancer, the recurrence of breast 
cancer increases. 
7.  Tibolone does not affect venous thromboem-
bolism and coronary artery disease. In case of 
administering tibolone to patients aged above 60 
years, there is an increased incidence of stroke. 
8.  Tibolone is effective in increasing muscle mass.
17.  Instructions for tissue-selective estrogen 
complex (TSEC) treatment
TSEC is a newly developed treatment that involves a 
combination of bazedoxifene, a SERM, and conjugated 
estrogen to improve drug tolerance of the existing pro-
gestogen to reduce the risk of breast cancer, breast pain, 
and vaginal bleeding in addition to treating menopaus-
al symptoms [203-206]. Combined estrogen/bazedoxi-
fene (CE/BZA) is used to treat menopausal symptoms 
and osteoporosis through the unique pharmacological 
properties and mechanism of action of bazedoxifene, 
which acts as an agonist to estrogen receptors located 
in the bone and as an antagonist to those located in the 
uterus or breast. Moreover, while retaining the advan-
tages of estrogen therapy, it secures stability against the 
endometrium. CE/BZA was approved by the Ministry 
of Food and Drug Safety in July 2014 for the treatment 
of VMS associated with menopause and the prevention 
of postmenopausal osteoporosis in women without an 
excised uterus.
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17-1. Effects on menopausal symptoms
CE/BZA significantly improves QoL by improving 
sleep disorder, GSM, and hot flush while reducing ir-
ritation in the endometrium [207-209].
1) Vasomotor symptoms
The reduced incidence of hot flushes due to CE/BZA 
treatment starts to significantly appear (P = 0.008) 
from the third week of intake in a previous study. The 
daily average incidence of hot flush occurrence after 12 
weeks of intake was reduced in the placebo group by 
51%, whereas it was significantly reduced by 74% in the 
CE/BZA group (P < 0.01) [207].
2) GSM
Compared with placebo, CE/BZA significantly in-
creased the number of vaginal epithelial cells and 
reduced the number of parabasal cells. According to 
clinical results, the effects of CE/BZA for improving 
sexual function and treating symptoms related to mod-
erate-to-severe genital atrophy as well as for alleviating 
dyspareunia have been proven [208].
3) QoL depending on sleep disorder
Compared with placebo, CE/BZA has been shown to 
significantly improve QoL related to health and sleep. 
After 12 months, the CE/BZA group experienced sig-
nificant improvement of sleep disorder and time taken 
to fall asleep. The vasomotor nerve function score as 
per The Menopause-Specific Quality of Life, which 
evaluates QoL related to menopause at 3–12 months, is 
also significantly improved [209].
17-2. Osteoporosis
CE/BZA increases bone density of the lumbar spine 
and femur and improves the markers of bone metabo-
lism [204,210]. A study was conducted for 1 year to 
compare the effect of CE/BZA on bone density with 
that of placebo and estrogen/MPA (CE/MPA) in a tar-
get group of 1,061 healthy menopausal women with 
ovaries who were aged 40–65 years. According to the 
results, CE/BZA significantly increased the bone den-
sity of the lumbar and femur and improved the bone 
metabolism markers [204].
17-3. Safety
CE/BZA has been shown to be safe for the endometri-
um [206,211] while having a very low level of adverse 
reactions to MHT, such as breast pain, vaginal bleeding, 
and increased breast density, which are similar to those 
using a placebo [204,205]. Lipid metabolisms showed a 
similar change as other MHT and did not lead to nega-
tive effect on hemostasis [212].
1) Increased breast density and breast tenderness
In recent studies, CE/BZA did not increase in inci-
dence of breast cancer, breast pressure, or breast density 
compared with placebo. On comparing the placebo 
group with the BZA 20 mg/CE 0.45 mg group and CE 
0.45 mg/MPA 1.5 mg group in a study targeting 940 
healthy menopausal women with ovaries who were 
aged 40–65 years, after 12 months, the CE/MPA group 
was observed to have a noticeably increased dense 
breast tissue ratio compared with that in the placebo 
group, whereas the CE/BZA group was confirmed to 
show no significant difference in breast density changes 
compared with the placebo group. Breast tenderness 
was similar to that in the placebo group. In the CE/
MPA group, breast tenderness was significantly severe 
[205].
2) Vaginal bleeding and endometrial proliferation
For menopausal women receiving MHT, vaginal 
bleeding is a common adverse reaction and is a reason 
for many patients to either never start or stop MHT 
[213]. Until 1 year from the time of beginning CE/BZA 
therapy, hemorrhage and petechial hemorrhage were 
not reported in 85.3%–99.2% of patients; this result was 
similar to that in the placebo group but was less than 
that in the CE/MPA control group (48.9%–83.2%; P < 
0.001) [204]. On checking the occurrence of endome-
trial proliferation 12 months after oral administration 
of placebo, raloxifene 60 mg, CE 0.625 or 0.45 mg, 
and BZA 10, 20, or 40 mg once a day to 1,843 healthy 
menopausal women to evaluate the safety of CE/BZA 
for the endometrium, less than 1% of patients showed 
endometrial proliferation after the 1-year treatment, 
and the minimum dose of BZA that could reduce the 
irritation of the endometrium due to CE was 20 mg 
[206,211].
3) Lipid and coagulation variables
Compared with placebo, CE/BZA reduced the levels 
of total cholesterol and LDL cholesterol while increas-
ing the level of HDL cholesterol. In contrast to pla-
cebo, for hemostasis variables, CE/BZA reduced the 
activation of fibrinogen, PAI-1, and antithrombin and 
increased the activation of plasminogen. CE/BZA was 
demonstrated to not cause a negative effect on the bal-
ance of lipid metabolism and hemostasis [212].
17-4. Recommendations from abroad
1) NAMS [2]
NAMS recommends CE/BZA as an effective MHT 
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for treatment of VMS and prevention of osteoporosis 
and fracture in menopausal women without an excised 
uterus and states that progestogen is not required as 
bazedoxifene protects the endometrium.
2) American Endocrine Society [214]
According to the clinical guidelines by the American 
Endocrine Society, CE/BZA could be used to prevent 
bone loss and alleviate VMS in menopausal women 
without an excised uterus as well as to treat side effects 
such as mood changes, breast tenderness, and proges-
togen-related vaginal bleeding. Moreover, CE/BZA 
was shown to improve QoL in menopausal patients by 
improving sleep disorders and reducing dyspareunia by 
increasing the maturity level of the vagina.
Key points:  Instructions for tissue-selective 
estrogen complex (TSEC) treat-
ment
1.  CE/BZA is effective in alleviating VMS such as 
hot flush and GSM including urogenital atrophy.
2.  CE/BZA significantly increases the bone density 
of the lumbar spine and hip joint.
3.  CE/BZA is associated with a low incidence of 
vaginal bleeding and breast pain and increased 
breast density.
4.  The safety of CE/BZA for the endometrium has 
been proven.
5.  No RCTs have been conducted with breast can-
cer, fracture, and cardiovascular disorder as the 
primary endpoints.
6.  In South Korea, no studies on VMS, increased 
breast density, breast tenderness, endometrial 
proliferation, vaginal bleeding, and osteoporosis 
have been conducted yet, but CE/BZA is being 
selected as one of the MHT options.
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